These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36692562)

  • 1. Novel Oral Polio Vaccine Safely Induces Antibodies Among Vaccine-Naive Infants.
    Slomski A
    JAMA; 2023 Jan; 329(4):279. PubMed ID: 36692562
    [No Abstract]   [Full Text] [Related]  

  • 2. The problems of poliovirus immunization.
    Fulginiti VA
    Hosp Pract; 1980 Aug; 15(8):61-7. PubMed ID: 6249713
    [No Abstract]   [Full Text] [Related]  

  • 3. The final phase of polio eradication: new vaccines and complex choices.
    Cochi SL; Linkins RW
    J Infect Dis; 2012 Jan; 205(2):169-71. PubMed ID: 22158681
    [No Abstract]   [Full Text] [Related]  

  • 4. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines.
    McBean AM; Thoms ML; Albrecht P; Cuthie JC; Bernier R
    Am J Epidemiol; 1988 Sep; 128(3):615-28. PubMed ID: 2843039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
    Macklin GR; Grassly NC; Sutter RW; Mach O; Bandyopadhyay AS; Edmunds WJ; O'Reilly KM
    Lancet Infect Dis; 2019 Oct; 19(10):1121-1128. PubMed ID: 31350192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WHO policy statement on polio vaccines.
    Wkly Epidemiol Rec; 1995 Dec; 70(49):346-7. PubMed ID: 8652353
    [No Abstract]   [Full Text] [Related]  

  • 8. Achieving and maintaining polio eradication--new strategies.
    Modlin J; Wenger J
    N Engl J Med; 2014 Oct; 371(16):1476-9. PubMed ID: 25317869
    [No Abstract]   [Full Text] [Related]  

  • 9. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
    Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
    Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis.
    Tang G; Yin W; Cao Y; Tan L; Wu S; Cao Y; Fu X; Yan J; Jiang X
    Hum Vaccin Immunother; 2018; 14(11):2636-2643. PubMed ID: 29985751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
    Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
    J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of poliomyelitis: a continuing paradox.
    Horstmann DM
    J Infect Dis; 1982 Oct; 146(4):540-51. PubMed ID: 6288809
    [No Abstract]   [Full Text] [Related]  

  • 16. A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania.
    Bandyopadhyay AS; Gast C; Brickley EB; Rüttimann R; Clemens R; Oberste MS; Weldon WC; Ackerman ME; Connor RI; Wieland-Alter WF; Wright P; Usonis V
    J Infect Dis; 2021 Jan; 223(1):119-127. PubMed ID: 32621741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Observation on safety of sequential vaccination schedule of different strain inactivated poliovirus vaccines].
    Huang ZY; Sun XD; Liu JC; Li Z; Ren J; Wu LL; Hu JY; Zhang JN
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 May; 40(5):565-570. PubMed ID: 31177739
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid and accurate identification of poliovirus strains used for vaccine production.
    Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
    J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.
    Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y
    Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
    Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
    Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.